Encompass Health (NYSE:EHC) Receives “Outperform” Rating from William Blair

William Blair reissued their outperform rating on shares of Encompass Health (NYSE:EHC) in a research note issued to investors on Friday morning,RTT News reports. William Blair also issued estimates for Encompass Health’s Q1 2025 earnings at $1.16 EPS, Q2 2025 earnings at $1.12 EPS, Q3 2025 earnings at $1.14 EPS, Q4 2025 earnings at $1.32 EPS and FY2026 earnings at $5.39 EPS.

Other research analysts have also recently issued reports about the stock. Truist Financial reissued a “buy” rating and set a $116.00 price objective (up from $108.00) on shares of Encompass Health in a research note on Wednesday, October 30th. Royal Bank of Canada upped their price objective on shares of Encompass Health from $105.00 to $110.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. KeyCorp upped their price objective on shares of Encompass Health from $115.00 to $117.00 and gave the company an “overweight” rating in a research note on Tuesday, October 29th. Finally, Barclays lifted their price objective on Encompass Health from $109.00 to $116.00 and gave the company an “overweight” rating in a research note on Tuesday, October 29th. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $107.33.

Encompass Health Stock Performance

Shares of EHC opened at $99.86 on Friday. The company’s 50 day simple moving average is $96.28 and its 200-day simple moving average is $95.19. Encompass Health has a 12-month low of $72.37 and a 12-month high of $104.55. The firm has a market cap of $10.06 billion, a PE ratio of 22.39, a price-to-earnings-growth ratio of 1.18 and a beta of 0.90. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.88.

Encompass Health (NYSE:EHC) last issued its earnings results on Thursday, February 6th. The company reported $1.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.12. Encompass Health had a return on equity of 18.06% and a net margin of 8.48%. As a group, equities analysts predict that Encompass Health will post 4.76 EPS for the current year.

Institutional Trading of Encompass Health

A number of hedge funds have recently bought and sold shares of the company. MassMutual Private Wealth & Trust FSB lifted its holdings in shares of Encompass Health by 87.8% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company’s stock valued at $27,000 after purchasing an additional 137 shares in the last quarter. UMB Bank n.a. lifted its stake in Encompass Health by 387.7% in the 3rd quarter. UMB Bank n.a. now owns 317 shares of the company’s stock worth $31,000 after acquiring an additional 252 shares in the last quarter. V Square Quantitative Management LLC lifted its position in shares of Encompass Health by 53.0% in the third quarter. V Square Quantitative Management LLC now owns 404 shares of the company’s stock worth $39,000 after purchasing an additional 140 shares in the last quarter. Avior Wealth Management LLC acquired a new stake in shares of Encompass Health during the third quarter worth approximately $40,000. Finally, Tompkins Financial Corp acquired a new position in Encompass Health in the 4th quarter valued at approximately $46,000. 97.25% of the stock is owned by hedge funds and other institutional investors.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.